Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hsi

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Pathology Informatics|January 7, 2014
Inter-reader variability in follicular lymphoma grading: Conventional and digital readingGerard Lozanski, Michael Pennell, Arwa Shana'ah, et al.
Seminars in Oncology|February 1, 2012
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah, Pierre Triozzi, Brian Rini, et al.
Cancer Medicine|December 22, 2018
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trialsFrederick Lansigan, Ian Barak, Brandelyn Pitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Blood|January 25, 2011
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalitiesSamar Farha, Kewal Asosingh, Weiling Xu, et al.
Blood|February 25, 2011
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemiaHideki Makishima, Anna M Jankowska, Michael A McDevitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignanciesHideki Makishima, Heather Cazzolli, Hadrian Szpurka, et al.
The Lancet. Haematology|March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trialsSonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemiaJulia T Geyer, Wayne Tam, Yen-Chun Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 7, 2018
A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 CriteriaElizabeth Margolskee, Geoff Mikita, Bryan Rea, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Pathology Informatics|January 7, 2014
Inter-reader variability in follicular lymphoma grading: Conventional and digital readingGerard Lozanski, Michael Pennell, Arwa Shana'ah, et al.
Seminars in Oncology|February 1, 2012
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesYogen Saunthararajah, Pierre Triozzi, Brian Rini, et al.
Cancer Medicine|December 22, 2018
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trialsFrederick Lansigan, Ian Barak, Brandelyn Pitcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance)Ann S LaCasce, Travis Dockter, Amy S Ruppert, et al.
Blood|January 25, 2011
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalitiesSamar Farha, Kewal Asosingh, Weiling Xu, et al.
Blood|February 25, 2011
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemiaHideki Makishima, Anna M Jankowska, Michael A McDevitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignanciesHideki Makishima, Heather Cazzolli, Hadrian Szpurka, et al.
The Lancet. Haematology|March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trialsSonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 27, 2017
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemiaJulia T Geyer, Wayne Tam, Yen-Chun Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 7, 2018
A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 CriteriaElizabeth Margolskee, Geoff Mikita, Bryan Rea, et al.
Pageof 4